SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of layoffs in India and the Philippines, with termination notices citing a scaled-down business assignment, have sparked concern that Innodata may have lost or reduced a major client project. Traders are divided between that revenue-risk interpretation and the view that the cuts reflect efficiency or a shift to contract workers, with the uncertainty weighing on shares ahead of Q3 results.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

A recent rebound that held near breakout levels has prompted bullish swing-trade setups and call buying ahead of earnings. Traders are watching for follow-through, while some remain cautious about weak housing demand and interest-rate sensitivity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on ImmunityBios upcoming QUILT-2.005 Phase 3 topline readout of ANKTIVA plus BCG for first-line bladder cancer; the company has completed the database lock and says an sBLA filing is on track for Q4. Traders are largely optimistic about the potential label expansion, while also watching Q3 results and debating whether the clinical and commercial momentum will justify the bullish expectations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp precious-metals selloff and a reported 52-week low, with traders citing Fed rate-hike expectations and possible forced liquidation as pressures. The community is split between calling gold a failed safe haven and viewing the decline as a buying opportunity, with some watching for support or a rebound.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI discussion centers on its prolonged weakness and concerns that Trump-family crypto monetization and potential token sales are weighing on sentiment. Bulls counter that a bank charter and USD1-related utility could support a rebound, though those catalysts are discussed largely as expectations, while skeptics see no near-term support.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is drawing attention after a sharp gain alongside elevated volatility and unusually heavy call activity. Traders are split between treating the move as a hedge against market risk and expecting the volatility spike to fade, citing the funds tendency to decay over time.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are framing disruptions to Qatari and other Middle Eastern LNG supply, including shipping risks around the Strait of Hormuz, as a potential tailwind for U.S. exporters and future contracting leverage at NextDecades Rio Grande project. Skeptics note that NEXT has not yet begun production and remains exposed to construction, financing, and execution risks ahead of planned first LNG output in 2027.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep selloff as investors await Q3 results to gauge whether Auvelitys Alzheimers-agitation launch is translating into paid prescriptions and whether commercial spending is delaying profitability. Some traders believe sampling and long-term-care channels understate demand, while others point to sluggish visible prescription growth, managements silence and cash-burn concerns.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 update sparked a sharp rally as traders focused on stronger profitability and cash generation, while revenue remained under pressure and BetterHelp continued to weigh on the growth outlook. Bulls are debating whether the results mark a turnaround and could pressure short sellers; skeptics see unresolved growth and execution risks.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and included a modest outlook increase, but the shares sold off sharply and reached a 52-week low. Traders disagree over whether the decline is excessive given the companys cash position and buyback, or justified by weak growth, reliance on an R&D grant, and concerns about competition and demand for higher-end driver-assistance systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE PR Newswire MIAMI, July 29, 2026 MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A.advised Entera Bio Ltd. (NASDAQ: ENTX), a...

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million.
Gossamer Bio (NASDAQ:GOSS) shares moved upwards byread more...

Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know

ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.

Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus

DELL, CAT and AMKR led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?

Equity

Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.


Entera Bio (ENTX) to Release Earnings on Friday

Entera Bio (NASDAQ:ENTX) will be releasing its Q1 2026 earnings after the market closes on Friday, May 8. (View Earnings Report at...

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What is HC Wainwright's Estimate for Entera Bio Q1 Earnings?

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0...

HC Wainwright Has Lowered Expectations for Entera Bio (NASDAQ:ENTX) Stock Price

HC Wainwright lowered their price objective on shares of Entera Bio from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...

Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near

Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the...

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Entera Bio Ltd

Bearish Sentiment

<ul class="summary-bullets"><li>The main measure of success in the upcoming trial will be how much bone density improves in the hip after one year of treatment.</li><li>Entera expects to begin the trial in late 2026 and report top-line results in the second half of 2028 — about a year earlier than previously planned.</li><li>The company’s earlier mid-stage study of the pill in 161 postmenopausal women met its goals, showing meaningful increases in bone density at the spine and hip.</li></ul>Shares of Entera Bio Ltd. (ENTX) surged 52% on Monday after the company announced encouraging feedback from the U.S. Food and Drug Administration on its registrational late-stage study design for its most advanced program, EB613.The stock is on track for its best day since March 2021, if gains hold.<h2 class="st-heading-2">FDA Aligns With Entera</h2>The FDA backed Entera’s plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis. The study will enroll roughly 750 patients and is designed to support an eventual application for FDA approval.Osteoporosis is a bone disease that occurs when the body loses too much bone, makes too little bone, or both. As a result, bones become weak, brittle, and highly susceptible to fractures, even from minor falls or bumps.<h2 class="st-heading-2">New Trial Outline</h2>The main measure of success in the upcoming trial will be how much bone density improves in the hip after one year of treatment. The company will also compare its pill to the existing injectable bone-building drug Forteo and include a smaller bone biopsy study in some patients. Patients who finish the main trial will continue in a follow-up study for up to two years to check longer-term safety and benefits.Entera expects to begin the trial in late 2026 and report top-line results in the second half of 2028 — about a year earlier than previously planned.Entera Bio is developing EB613 as the first oral version of a bone-building treatment for osteoporosis. All currently approved bone-building drugs must be given by daily injection and are used by only a small portion of patients who could benefit.The company’s earlier mid-stage study of the pill in 161 postmenopausal women met its goals, showing meaningful increases in bone density at the spine and hip. More recent early testing also showed that a single-tablet version performed similarly to the multi-tablet version used before and to the injectable Forteo.<h2 class="st-heading-2">How Did ENTX Retail Traders React?</h2>On Stocktwits, retail sentiment around ENTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user voiced optimism in the market potential of the drug, thanks to its ease of administration.<stembedurl>https://www.stocktwits.com/OldManLogan/message/657054690</stembedurl>The user also applauded the news as massive.<stembedurl>https://www.stocktwits.com/OldManLogan/message/657033145</stembedurl>According to data from Koyfin, the analyst covering ENTX rates it a ‘Buy’ with a price target of $9, representing a potential upside of about 643% from the stock’s last close.<a href="https://stocktwits.com/symbol/ENTX">ENTX stock</a> has gained about 7% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/googl-stock-tumbles-after-losing-top-ai-talent-to-openai-anthropic/cZKMcYnR792">Did Google’s AI Ambitions Take A Hit Twice In A Week? What Investors Need To Know</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Entera Bio Ltd. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ENTX 🏥 

Entera Bio Ltd. announced post-hoc Phase 2 data showing EB613 produced greater bone mineral density gains and anabolic effects in postmenopausal women with osteoporosis (T-scores ≤ -2.5) versus osteopenia, supporting the Phase 3 study population. 

Curated for market relevance

Feed

News

Sentiment

Earnings

Fundamentals

Info

ENTX Entera Bio Ltd

Fundamentals

Latest ENTX News